YEM Search

搜索结果

DUT

靶点ID:TCMBANKGE011753

靶点别名:dUTPase

靶点描述:deoxyuridine triphosphatase

染色体:15

染色体位置:15q21.1

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:3078

OMIM_Link:601266

Ensembl_Link:ENSG00000128951

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN012700	coumestrol	NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA	C15H8O5	268.22	C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
TCMBANKIN042260	Teresantalol	Tricyclo[2.2.1.0(2,6)]heptane-3-methanol, 2,3-dimethyl-; 2,3-Dimethyltricyclo[2.2.1.02,6]heptane-3-methanol; {2,3-DIMETHYLTRICYCLO[2.2.1.0(2),?]HEPTAN-3-YL}METHANOL; ZWUWJJHLJNLVDD-UHFFFAOYSA-N; 10-hydroxytricyclene; AKOS024262936; 2,3-Dimethyltricyclo[2.2.1.02,6]heptane-3-methanol, 9CI; {2,3-dimethyltricyclo[2.2.1.0;{2,6}]heptan-3-yl}methanol; 2,3-Dimethyl-Tricyclo[2.2.1.0(2,6)]heptane-3-methanol; Tricyclo[2.2.1.0(2,6)]heptane-3-methanol, 2,3-dimethyl-, stereoisomer; AC1LB8D4; Teresantalol; 29550-55-8; CTK8A1990		152.23 g/mol
TCMBANKIN043330	β-Hydroxyisovalerylshikonin	beta-hydroxyisovalerylshikonin; beta-hydro-xyisovalerylshikonin		388.4 g/mol
TCMBANKIN058500	DUR	D5412_SIGMA; AIDS113822; ZINC00155696; BRN 0024433; 4-24-00-01200 (Beilstein Handbook Reference); 1-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1-H-pyrimidine-2,4-dione; NCGC00142492-01; 2'-Deoxyuridine; 1-[(2R,4S,5R)-4-hydroxy-5-methylol-tetrahydrofuran-2-yl]pyrimidine-2,4-quinone; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; C00526; CCRIS 2832; AIDS-113822; MLS001066344; dURD; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-erythro-ribofuranosyl)-; NSC 23615; SMR000112296; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-tetrahydrofuranyl]pyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; 20649-53-0; ST057093; EINECS 213-455-7; 2′-Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; deoxyuridine	C9H12N2O5	228.2 g/mol	C1C(C(OC1N2C=CC(=O)NC2=O)CO)O
TCMBANKIN060889	delta(9)-tetrahydrocannabinol		C21H30O2	314.5 g/mol	CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
TCMBANKIN060892	tetrahydrocannabinol delta8				CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000023		Skin and Connective Tissue Diseases; Immune System Diseases	Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI004983		Neoplasms; Female Urogenital Diseases and Pregnancy Complications	-	Neoplastic Process	disease
TCMBANKDI006765		Pathological Conditions, Signs and Symptoms; Neoplasms; Infections; Stomatognathic Diseases	Abnormality of head or neck	Neoplastic Process	disease
TCMBANKDI009912		Pathological Conditions, Signs and Symptoms	Abnormality of metabolism/homeostasis	Sign or Symptom	phenotype
TCMBANKDI011234		Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases	-	Disease or Syndrome	disease
TCMBANKDI011814		-	-	Neoplastic Process	phenotype
TCMBANKDI017024		Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI020602		Male Urogenital Diseases	Abnormality of the genitourinary system	Disease or Syndrome	disease
TCMBANKDI024535		Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI026922		Infections; Nervous System Diseases; Animal Diseases	-	Disease or Syndrome	disease
TCMBANKDI031523		Hemic and Lymphatic Diseases	Abnormality of blood and blood-forming tissues	Disease or Syndrome	disease
TCMBANKDI032162		Infections	-	Disease or Syndrome	group
TCMBANKDI032440		Pathological Conditions, Signs and Symptoms	-	Sign or Symptom	phenotype